Druck Icon

NEMOD Immuntherapie transfers all assets and liabilities to newly founded NEMOD Biotherapeutics GmbH & Co. KG

Berlin, 19.9.03 NEMOD Immuntherapie GmbH, a drug discovery company focusing on oncological indications, today announced that it has transferred all of its assets and liabilities to the newly founded partnership company NEMOD Biotherapeutics GmbH & Co. KG.

"The legal transformation into a partnership reestablishes the possibility of transferring losses to corporate companies. With this step we open NEMOD for new investors who should help us in executing our clinical development programs starting 2004", said Dr. Andreas Hey, COO of NEMOD. "With the name change from "Immuntherapie" into "Biotherapeutics" we would like to express that we will not restrict our oncology programs to immunotherapeutic approaches only."

NEMOD Biotherapeutics GmbH & Co. KG (www.nemod.com) is a drug discovery company affiliated with publicly listed Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE 00056597000, German Prime Standard). NEMOD´s development program focuses on oncological indications like gastric, colon, liver, and breast cancer. Lead projects are PankoMab™, a therapeutic tumor antibody, and NemodDC™, the currently worldwide only cell line, which allows harvesting of human dendritic cells without human donors.

The Board of Directors